Understanding the Medical Applications of THC, CBD, and CBN
Medical Applications and Use Cases
- Pain Relief: Effective for chronic pain relief but may cause euphoria and sedation. Starting dose: 2.5-5mg THC.
- Anxiety Reduction: May reduce anxiety at low doses but can exacerbate it at higher doses.
- Anti-Inflammation: Shows promise in reducing inflammation but is less studied than CBD.
- Sleep Aid: Often used for insomnia but may lead to grogginess upon waking.
- Pain Relief: Effective for neuropathic pain, less psychoactive impact. Starting dose: 5-10mg CBD.
- Anxiety Reduction: Widely used for anxiety and PTSD.
- Anti-Inflammation: Proven efficacy for treating inflammation.
- Epilepsy Control: Proven effective for certain forms of epilepsy such as Dravet syndrome.
- Pain Relief: Less potent than THC and CBD but has potential. Starting dose: 2.5-5mg CBN.
- Sleep Aid: Known for its sedative effects.
- Anti-Inflammation: Some evidence supporting anti-inflammatory potential.
- Antibacterial: Exhibits antibacterial properties, especially against MRSA.
Comprehensive Comparison Table
|Aspect||Questions to Ask||THC||CBD||CBN|
|Pain Relief||What type of pain do I have?||Effective for chronic pain||Effective for neuropathic pain||Less potent but promising|
|Anxiety Reduction||Am I prone to THC-induced anxiety?||Dose-dependent effects||Widely used for anxiety||Not well-studied|
|Anti-Inflammation||Do I have a gastrointestinal disorder?||Promising but less studied||Proven efficacy||Some evidence|
|Epilepsy Control||Do I have a form of drug-resistant epilepsy?||Limited studies||Effective for Dravet syndrome||Not well-studied|
|Sleep Aid||Do I have trouble falling asleep or staying asleep||Effective but may cause grogginess||Limited evidence||Known for sedative effects|
|Antibacterial||Am I looking for antibacterial properties?||Limited evidence||Limited evidence||Effective against MRSA|
- Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.
- MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12-19.
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Schmidlkofer, S. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456-2473.
- Mechoulam, R., & Hanuš, L. (2002). Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chemistry and physics of lipids, 121(1-2), 35-43.
- Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., … & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. Journal of Natural Products, 71(8), 1427-1430.
Medical Illnesses and Diagnoses for Caution
- Cardiovascular Diseases
- Psychotic Disorders
- Liver Disorders
For specialized care for these conditions, consult Dr. Benjamin Caplan at CED Clinic.
📗 Note: The diagram’s a swig of soda; the book’s a sip of fine wine. Uncork it here 📗